NEJM publishes Ebola vaccine data

Single doses of Ebola vaccine RVSV-EBOV ( VSV-ZEBOV; VSV-EBOV) led to an immune response in multiple Phase I trials conducted in the U.S., Switzerland, Germany, Gabon and Kenya. No serious vaccine-related adverse events were reported. Results were published in two reports in the New England Journal of Medicine on Wednesday.

Merck & Co. Inc. (NYSE:MRK) obtained exclusive worldwide development and commercialization rights to RVSV-EBOV in November 2014 from NewLink Genetics Corp. (NASDAQ:NLNK). The vaccine originally was developed by the Public Health Agency of Canada. ...